The synthesis of N- derivative

A novel series of N-(4-aryl-thiazol-2-yl)-N[sup.1]-(4,5,6,7-tetrahydro-3Ð-azepin-2-yl)-hydrazine derivatives were synthesized by interaction of equimolar quantities of substituted [ALPHA]-bromacetophenones with thiosemicarbazide and characterized on the basis of their elemental analyses and spectral data. Study of cardioprotective activity of the all new products in comparison to levocarnitine and its synthetic analogue mildronate were carried out. Thus, specified results indicate, N-[(4[sup.1]-methoxyphenyl)-thiazol-2-yl)]-N[sup.1]-(4,5,6,7-tetrahydro-3Ð-azepin-2-yl)-hydrazine hydrobromide was influenced deceleration of contractive response of smooth muscles to hypoxia 13.2% more effective than levocarnitine and 6.85% more effective than mildronate and were shown pronounced cardioprotective properties. Obtained data justifies further study of N-(4-aryl-thiazol-2-yl)-N[sup.1]-(4,5,6,7-tetrahydro-3Ð-azepin-yl)-hydrazine derivatives as new potential cardioprotective drugs for treatment of various cardiac diseases. Keywords: Cardioprotective activity, Mildronate, Levocarnitine, N-(4-aryl-thiazol-2-yl)-N[sup.1]-(4, 5, 6, 7-tetrahydro-3H-azepin-2-yl)-hydrazine derivatives